ProQR Therapeutics (PRQR) Downgraded by Zacks Investment Research to Hold

ProQR Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  ProQR Therapeutics Downgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More ProQR Therapeutics (PRQR) Downgraded by Zacks Investment Research to Hold